Fertility warning
This medicine may affect fertility.
Leaflet MITOMICINA MEDAC 1mg / ml powder for solution for injection / infusion or intravesical solution
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Mitomycin is a chemotherapy drug used for the treatment of certain types of cancer, including gastric cancer, pancreatic cancer, and bladder cancer. It acts as an alkylating agent, interfering with DNA synthesis in cancer cells and inhibiting their division.
The medication is administered intravenously or intravesically, depending on the type and location of the cancer. It is effective in reducing tumor size and slowing disease progression.
Side effects may include nausea, vomiting, bone marrow suppression, increased risk of infections, and, in rare cases, pulmonary or renal toxicity. Close monitoring is essential during treatment.
Consult your doctor to discuss the benefits and risks of treatment with Mitomycin. This medication must be administered under the supervision of an oncology specialist.
The medication is administered intravenously or intravesically, depending on the type and location of the cancer. It is effective in reducing tumor size and slowing disease progression.
Side effects may include nausea, vomiting, bone marrow suppression, increased risk of infections, and, in rare cases, pulmonary or renal toxicity. Close monitoring is essential during treatment.
Consult your doctor to discuss the benefits and risks of treatment with Mitomycin. This medication must be administered under the supervision of an oncology specialist.
General data about MITOMICINA MEDAC 1mg / ml
- Substance:
- mitomycin
- Date of latest medicines list:
- 01-06-2016
- Product code:
- W62643001
- Concentration:
- 1mg / ml
- Pharmaceutical form:
- powder for solution for injection / infusion or intravesical solution
- Quantity:
- 1
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for mitomycin
Concentrations available for mitomycin
- 1mg/ml
- 20mg
- 40mg